DTIL Precision BioSciences, Inc.
6.250USD+0.81%Mkt Cap: 172.51M $P/E: —1d ago
Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing therapies for gene edits, including gene insertion, excision, and elimination in the United States. The company offers ARC…
Industry Peers
Biotechnology$128.08BUSDP/E 29.4
$78.44BUSD
$76.40BUSDP/E 18.4
$57.03BUSDP/E 37.3
$58.08BUSDP/E 35.4
$42.24BUSDP/E 18.0
$43.05BUSD
$41.41BUSDP/E 65.1
$32.80BUSDP/E 30.2
$30.03BUSDP/E 37.8
$25.10BUSD
$23.93BUSD
$22.99BUSDP/E 14.5
$22.27BUSDP/E 30.7
$22.54BUSDP/E 28.9
$22.22BUSD
$15.03BUSDP/E 17.5
$15.01BUSDP/E 15.8
$14.48BUSDP/E 18.4
$14.32BUSD
| Headline | Source | Time |
|---|---|---|
Older | ||
 Gene-Editing Powerhouse And Its Rivals Surge Toward A Breakout Crispr stock, alongside other gene-editing equities, pulled a bullish move Thursday — bounding for a breakout from a cup-with-handle base. | ||